

04/20/01

J1031 U.S. PTO

Berlex Laboratories, Inc.  
15049 San Pablo Avenue  
PO Box 4099  
Richmond, CA 94804-0099

**BOX PATENT APPLICATION**  
**ASSISTANT COMMISSIONER FOR PATENTS**  
**Washington, DC 20231**

Sir:  
Transmitted herewith for filing under 37 CFR §1.53(b) is the  
☒ patent application ☐ continuation patent application,  
☐ divisional patent application or ☐ continuation-in-part  
patent application of

Inventors Identifier: Ted LAU, Richard J. LIN, Deborah PARKES, Gordon PARRY, Douglas W. SCHNEIDER, Renate STEINBRECHER, Pamela Toy VAN HEUIT, and John WU

For: DNA ENCODING A NOVEL PROST 03 POLYPEPTIDE

- ☐ This application claims priority from each of the following Application No./filing dates:  
US Serial No. \_\_\_\_\_/\_\_\_\_\_ the disclosure(s) of which is (are) incorporated by reference.  
☐ Please amend this application by adding the following before the first sentence: -This application is a ☐ continuation ☐ division  
of and claims the benefit of U.S. Application No. \_\_\_\_\_ filed \_\_\_\_\_, the disclosure of which is incorporated by reference.--  
☒ The benefit under 35 U.S.C. Section 119 is claimed of the filing date of: U.S. Provisional Application No. 60/200,065, filed April  
27, 2000.

Enclosed are:

- ☒ 12 sheets of ☐ formal ☒ informal drawings(s) and 49 pages of specifications including description, claims and abstract.  
☒ Transmittal of Sequence Listing  
☒ 12 pages of Sequence Listing with computer readable disk.  
☐ An assignment of the invention to \_\_\_\_\_.  
☒ A ☐ signed ☒ unsigned Declaration and Power of Attorney.  
☐ A ☐ signed ☐ unsigned Declaration  
☐ A Power of Attorney by Assignee with Certificate Under 37 CFR Section 3.73(b).  
☐ A certified copy of a \_\_\_\_\_.  
☒ Information Disclosure Statement under 37 CFR 1.97.  
☐ A petition to extend time to respond in the parent application  
☐ Notification of change of ☐ power of attorney ☐ correspondence address filed in prior application.  
☐ Please cancel claim(s) \_\_\_\_\_.  
☐ Preliminary Amendment  
☒ Return postcard

	(Col. 1)	(Col. 2)		
FOR:	NO FILED	NO EXTRA	RATE	FEE
BASIC FEE				\$710.00
TOTAL CLAIMS	38 - 20 =	* 18	x \$18.00 =	324.00
INDEPENDENT CLAIMS	10 - 3 =	* 7	x \$80.00 =	560.00
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED			= \$270.00 =	
* if the difference in Col. 1 is less than zero, enter "0" in Col. 2				
			<b>TOTAL</b>	<b>\$1594.00</b>

- ☐ There is no increase in the accompanying Preliminary Amendment in the number of independent, dependent or multiple  
dependent claims beyond those previously paid for.

Please charge Deposit Account 02-2117 as follows:

- ☒ Filing fee  
☒ Any additional fees associated with this paper or  
during the pendency of this application.  
☐ The issue fee set in 37 CFR 1.18 at or before mailing of the Notice  
of Allowance, pursuant to 37 CFR 1.311(b).

Respectfully submitted,

*Wendy L. Washtien*

Wendy L. Washtien  
Reg. No. 36,301  
Patent Agent for Applicants

Telephone: 510 262-5411 Facsimile: 510 262-7095

Date: April 19, 2001

Atty. Docket No. 51831AUSM1

"Express Mail" Label No. EL414974440US  
Date of Deposit April 20, 2001

I hereby certify that this is being deposited with the  
United States Postal Service "Express Mail Post Office  
to Addressee" service under 37 CFR 1.10 on the date  
indicated above and is addressed to:

Box Patent Application  
Assistant Commissioner for Patents  
Washington, DC 20231

By: *Carole J. Smith*

4-23-01  
A  
BOX  
Self

JC903 U.S. PTO  
09/838785  
04/20/01

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of :  
 Lau et al. :  
 Serial No.: Not yet known : Group Art Unit: Not yet known  
 Filed: Filed herewith : Examiner: Not yet known  
 For DNA ENCODING A NOVEL PROST 03 POLYPEPTIDE

Honorable Commissioner of Patents and Trademarks  
 Washington, D.C. 20231

Sir:

## TRANSMITTAL OF SEQUENCE LISTING

Applicants hereby submit a Sequence Listing and a Sequence Listing in computer readable form (as required under 37 CFR §1.821-1.825).

Applicants' attorney attests that the information recorded in computer readable form is identical to the written "Sequence Listing", as required under 37 CFR §1.821(f). This submission introduces no new matter, since the enclosed sequences are identical to the sequences which were submitted in the original patent application.

Respectfully submitted,

*Wendy L. Washtien*

Wendy L. Washtien, Ph.D.

Agent for Applicants

Reg. No. 36,301

Berlex Biosciences  
 15049 San Pablo Avenue  
 P.O. Box 4099  
 Richmond, CA 94804-0099  
 Telephone: (510) 262-5411  
 Fax: (510) 262-7095  
 Date: April 5, 2001